Application Effect of Nintedanib Combined with Omeprazole and Mosapride in the Treatment of Patients with Idiopathic Pulmonary Fibrosis

BAI Shaohua, LI Jin, LI Zhengchuan, YANG Hua

Journal of Hunan Normal University(Medical Science) ›› 2026, Vol. 23 ›› Issue (2) : 143-147.

PDF(2100 KB)
PDF(2100 KB)
Journal of Hunan Normal University(Medical Science) ›› 2026, Vol. 23 ›› Issue (2) : 143-147.
Clinical Medicine

Application Effect of Nintedanib Combined with Omeprazole and Mosapride in the Treatment of Patients with Idiopathic Pulmonary Fibrosis

  • BAI Shaohua, LI Jin, LI Zhengchuan, YANG Hua
Author information +
History +

Abstract

Objective To investigate the improvement effect and clinical value of the anti-reflux and anti-fibrotic combination regimen of nintedanib combined with omeprazole and mosapride on lung function and blood gas indexes in patients with idiopathic pulmonary fibrosis (IPF). Methods The conventional group was given nintedanib monotherapy for anti-fibrosis, and the combination group was combined with omeprazole + mosapride for anti-reflux treatment on the basis of the conventional group. Both groups were treated for 12 consecutive months. The lung function indexes[diffusing capacity for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) ]and blood gas indexes[arterial oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) ]of the two groups before treatment and at 3, 6, 9 and 12 months after treatment were detected. The quality of life at 6 and 12 months after treatment was evaluated by modified Medical Research Council (mMRC) and St. George's Respiratory Questionnaire (SGRQ). The frequency of acute exacerbations was counted during 24 months of follow-up. Results The DLCO, FEV1 and FVC of the combination group at 3, 6, 9 and 12 months after treatment were significantly higher than those of the conventional group during the same period (P<0.05). The SaO2 and PaO2 of the combination group at each time point of treatment were higher than those of the conventional group, and PaCO2 was lower than that of the conventional group (P<0.05). The mMRC scores and SGRQ scores of the combination group at 6 and 12 months after treatment were better than those of the conventional group during the same period (P<0.05). The acute exacerbation rate of the combination group was 12.50% at 12 months after treatment and 20.83% at 24 months of follow-up, which were lower than 31.25% and 52.08% in the conventional group (P<0.05). Conclusion Anti-reflux therapy combined with anti-fibrotic medications significantly improves pulmonary function, gas exchange parameters, and quality of life in patients with IPF and reduces the frequency of acute exacerbations.

Key words

idiopathic pulmonary fibrosis / anti-reflux therapy / anti-fibrotic medications / pulmonary function

Cite this article

Download Citations
BAI Shaohua, LI Jin, LI Zhengchuan, YANG Hua. Application Effect of Nintedanib Combined with Omeprazole and Mosapride in the Treatment of Patients with Idiopathic Pulmonary Fibrosis[J]. Journal of Hunan Normal University(Medical Science). 2026, 23(2): 143-147

References

[1] 白君, 陈珠妮, 叶景焕, 等. 双氢青蒿素对小鼠肺纤维化的影响及作用机制[J]. 中南医学科学杂志, 2023, 51(6): 848-852.
[2] SPAGNOLO P, DISTLER O, RYERSON CJ, et al.Mechanisms of progressive fibrosis in connective tissue disease (CTD) -associated interstitial lung diseases[J]. Ann Rheum Dis, 2021, 80(2): 143-150.
[3] 李蒙, 张静静, 李向南, 等. 十二指肠结扎对大鼠胃食管反流及博莱霉素肺纤维化的影响[J]. 中华医学杂志, 2021, 101(21): 1598-1605.
[4] AMATI F, STAINER A, POLELLI V, et al.Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review[J]. Int J Mol Sci, 2023, 24(9): 7849.
[5] 黄丽惠, 王喆, 刘晓菊, 等. 特发性肺纤维化诊断方法研究进展[J]. 国际呼吸杂志, 2023, 43(11): 1333-1337.
[6] 吴宣谕, 肖祥, 陈梦秋, 等. “聚于胃, 关于肺”视角下探索麦门冬汤治疗胃食管反流病与特发性肺纤维化共病机制[J]. 中草药, 2025, 56(6): 2052-2065.
[7] WU S, YIN L, HAN K, et al.NAT10 accelerates pulmonary fibrosis through N4-acetylated TGFB1-initiated epithelial-to-mesenchymal transition upon ambient fine particulate matter exposure[J]. Environ Pollut, 2023, 322: 121149.
[8] CORTE TJ, BEHR J, COTTIN V, et al.Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial[J]. Am J Respir Crit Care Med, 2025, 211(2): 230-238.
[9] 李晓雯, 潘玲, 叶欣鑫, 等. 特发性肺纤维化合并胃食管反流的研究进展[J]. 中国医学创新, 2023, 20(25): 185-188.
[10] 吕昆明, 王沙沙, 万军, 等. 胃食管反流病与特发性肺纤维化关系的研究进展[J]. 中华胃肠内镜电子杂志, 2023, 10(2): 121-124.
[11] CHEN P, XIE L, MA L, et al.Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease[J]. IET Syst Biol, 2023, 17(6): 352-365.
[12] 王帅, 王亚文, 邹永祎, 等. 尼达尼布治疗特发性肺纤维化92例对肺功能和肺纤维化指标的影响及不良反应分析[J]. 安徽医药, 2023, 27(4): 826-829.
[13] 汪泓, 刘兆云, 曹中保. 替普瑞酮辅助奥美拉唑以及莫沙必利对反流性食管炎患者的临床治疗效果研究[J]. 实用药物与临床, 2022, 25(2): 144-147.
[14] YANG M, DONG J, AN J, et al.Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis[J]. J Thorac Dis, 2021, 13(10): 5776-5787.
[15] BLOEM AEM, MOSTARD RLM, STOOT N, et al.Patient activation for self-management in patients with idiopathic pulmonary fibrosis or sarcoidosis[J]. Respiration, 2022, 101(1): 76-83.
[16] 杨东明, 聂建军, 任蔚, 等. 尼达尼布联合汉防己甲素治疗结缔组织病相关肺间质纤维化患者的临床研究[J]. 中国临床药理学杂志, 2024, 40(19): 2781-2785.
[17] REYNOLDS CJ, DEL GRECO MF, ALLEN RJ, et al.The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study[J]. Eur Respir J, 2023, 61(5): 2201585.
[18] 唐晓媛, 曾省都. 奥美拉唑联合莫沙必利治疗特发性肺纤维化的疗效[J]. 深圳中西医结合杂志, 2019, 29(24): 97-98.
[19] 周璇, 谢莉, 邹娟. 尼达尼布对特发性肺纤维化肺功能, 肺纤维化程度及PDGF, PGE2, TGF-β1的影响[J]. 中华肺部疾病杂志电子版, 2024, 17(3): 368-372.
PDF(2100 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉